NeoGenesis in Drug-Discovery Deal With Schering-Plough | GenomeWeb

NEW YORK, Aug. 6 – NeoGenesis and Schering-Plough Corporation have partnered to discover small-molecule drug leads, the companies announced on Monday.

Under the deal, NeoGenesis will employ its Automated Ligand Identification System (ALIS) and its neoMorph compound library to help Schering-Plough discover a range of antiviral candidates. In exchange, the drug giant will outlay research and development funding as well as an undisclosed equity investment in NeoGenesis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.